FR2842525B1 - Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant - Google Patents

Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant

Info

Publication number
FR2842525B1
FR2842525B1 FR0208948A FR0208948A FR2842525B1 FR 2842525 B1 FR2842525 B1 FR 2842525B1 FR 0208948 A FR0208948 A FR 0208948A FR 0208948 A FR0208948 A FR 0208948A FR 2842525 B1 FR2842525 B1 FR 2842525B1
Authority
FR
France
Prior art keywords
guanidinocarbonyl
medicaments
heteroaryl
preparation
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0208948A
Other languages
English (en)
Other versions
FR2842525A1 (fr
Inventor
Baptiste Ronan
Jean Christophe Carry
Pascal Desmazeau
Serge Mignani
Jean Bouquerel
Borella Arielle Genevois
Heinz Werner Kleeman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0208948A priority Critical patent/FR2842525B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to PCT/EP2003/007023 priority patent/WO2004007479A1/fr
Priority to MXPA05000268A priority patent/MXPA05000268A/es
Priority to EP03763685A priority patent/EP1530566A1/fr
Priority to BR0312701-0A priority patent/BR0312701A/pt
Priority to JP2004520458A priority patent/JP4751064B2/ja
Priority to AU2003250873A priority patent/AU2003250873A1/en
Priority to CA002492421A priority patent/CA2492421A1/fr
Priority to TW092119093A priority patent/TW200409766A/zh
Priority to PE2003000701A priority patent/PE20040659A1/es
Priority to AR20030102528A priority patent/AR040564A1/es
Priority to US10/749,631 priority patent/US7638521B2/en
Publication of FR2842525A1 publication Critical patent/FR2842525A1/fr
Priority to IL16609805A priority patent/IL166098A0/xx
Application granted granted Critical
Publication of FR2842525B1 publication Critical patent/FR2842525B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR0208948A 2002-07-16 2002-07-16 Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant Expired - Lifetime FR2842525B1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
FR0208948A FR2842525B1 (fr) 2002-07-16 2002-07-16 Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant
CA002492421A CA2492421A1 (fr) 2002-07-16 2003-07-02 Derives de 3-guanidinocarbonyle-1-heteroaryle-indole, procede de preparation associe, leur utilisation comme medicaments, et compositions pharmaceutiques les contenant
EP03763685A EP1530566A1 (fr) 2002-07-16 2003-07-02 Derives de 3-guanidinocarbonyle-1-heteroaryle-indole, procede de preparation associe, leur utilisation comme medicaments, et compositions pharmaceutiques les contenant
BR0312701-0A BR0312701A (pt) 2002-07-16 2003-07-02 Derivados de 3-guanidinocarbonil-1-hete-roaril-indol, processo de preparação, seu uso como medicamentos e composições farmacêuticas os compreendendo
JP2004520458A JP4751064B2 (ja) 2002-07-16 2003-07-02 ３−グアニジノカルボニル−１−ヘテロアリール−インドール誘導体、製造方法、医薬としてのそれらの使用並びにそれらを含有する医薬組成物
AU2003250873A AU2003250873A1 (en) 2002-07-16 2003-07-02 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them
PCT/EP2003/007023 WO2004007479A1 (fr) 2002-07-16 2003-07-02 Derives de 3-guanidinocarbonyle-1-heteroaryle-indole, procede de preparation associe, leur utilisation comme medicaments, et compositions pharmaceutiques les contenant
MXPA05000268A MXPA05000268A (es) 2002-07-16 2003-07-02 Derivados de 3-guanidinocarbonil-1-heteroaril-indol, procedimiento de preparacion, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
PE2003000701A PE20040659A1 (es) 2002-07-16 2003-07-14 Derivados de 3-guanidinocarbonil-1-heteroaril-indol, procedimiento de preparacion y composiciones farmaceuticas que los comprenden
TW092119093A TW200409766A (en) 2002-07-16 2003-07-14 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them
AR20030102528A AR040564A1 (es) 2002-07-16 2003-07-14 Derivados de 3 guanidinocarbonil- 1- heteroaril- indol, procedimiento de preparacion, su uso como medicamentos, y composiciones farmaceuticas que los comprenden
US10/749,631 US7638521B2 (en) 2002-07-16 2003-12-31 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them
IL16609805A IL166098A0 (en) 2002-07-16 2005-01-02 3-guanindinocarbonyl-1-heteroaryl-indole derivatives preparation process their use as medicaments and pharmaceutical compositions comprising them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0208948A FR2842525B1 (fr) 2002-07-16 2002-07-16 Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant

Publications (2)

Publication Number Publication Date
FR2842525A1 FR2842525A1 (fr) 2004-01-23
FR2842525B1 true FR2842525B1 (fr) 2005-05-13

Family

ID=29797441

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0208948A Expired - Lifetime FR2842525B1 (fr) 2002-07-16 2002-07-16 Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant

Country Status (13)

Country Link
US (1) US7638521B2 (fr)
EP (1) EP1530566A1 (fr)
JP (1) JP4751064B2 (fr)
AR (1) AR040564A1 (fr)
AU (1) AU2003250873A1 (fr)
BR (1) BR0312701A (fr)
CA (1) CA2492421A1 (fr)
FR (1) FR2842525B1 (fr)
IL (1) IL166098A0 (fr)
MX (1) MXPA05000268A (fr)
PE (1) PE20040659A1 (fr)
TW (1) TW200409766A (fr)
WO (1) WO2004007479A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230007B2 (en) 2003-06-12 2007-06-12 Sanofi-Aventis Deutschland Gmbh Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
EP1667683A4 (fr) * 2003-09-23 2009-04-29 Merck & Co Inc Inhibiteurs des canaux potassiques a la quinoleine
CA2575808A1 (fr) * 2004-08-02 2006-02-16 Osi Pharmaceuticals, Inc. Composes a base de pyrrolopyrimidine a substitution arylamine inhibiteurs de kinases multiples
EP1991540A1 (fr) * 2006-02-21 2008-11-19 Amgen Inc. Dérivés cinnoline comme inhibiteurs de phosphodiestérase 10
AU2007221049A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
US20090099175A1 (en) * 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
WO2007103554A1 (fr) * 2006-03-08 2007-09-13 Amgen Inc. Dérivés de quinoline et d'isoquinoline en tant qu'inhibiteurs de phosphodiestérase 10
US8580803B2 (en) 2009-12-30 2013-11-12 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
MX2019002212A (es) 2016-08-24 2019-07-08 Arqule Inc Compuestos de amino-pirrolo-pirimidinona y metodos de uso de los mismos.
CN111018836A (zh) * 2019-12-31 2020-04-17 南京福斯特牧业科技有限公司 一种增效磺胺类药物作用的嘧啶制剂及其制法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2121391A1 (fr) * 1993-04-28 1994-10-29 Atsuyuki Kojima Derives d'indoloylguanidine
JP3162572B2 (ja) * 1993-04-28 2001-05-08 住友製薬株式会社 インドロイルグアニジン誘導体
US5852046A (en) 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
EP0639573A1 (fr) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Hétérocycles à cinq chaînons benzocondensés, procédé pour leur préparation, leur utilisation comme médicament et comme diagnostique aussi bien que les produits pharmaceutiques le contenant
EP1454902A1 (fr) * 1998-02-27 2004-09-08 Pfizer Products Inc. Dérivés de N-carbonyl-guanidine à cycle di- ou triaza-pentagonal doublement insaturé et substitué pour le traitement de l'ischémie
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
FR2842526B1 (fr) * 2002-07-16 2007-07-13 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments

Also Published As

Publication number Publication date
JP4751064B2 (ja) 2011-08-17
US7638521B2 (en) 2009-12-29
BR0312701A (pt) 2005-04-26
WO2004007479A1 (fr) 2004-01-22
FR2842525A1 (fr) 2004-01-23
AR040564A1 (es) 2005-04-13
PE20040659A1 (es) 2004-11-09
TW200409766A (en) 2004-06-16
CA2492421A1 (fr) 2004-01-22
JP2006501190A (ja) 2006-01-12
AU2003250873A1 (en) 2004-02-02
IL166098A0 (en) 2006-01-15
MXPA05000268A (es) 2005-03-31
EP1530566A1 (fr) 2005-05-18
US20040214820A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
FR2836915B1 (fr) Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2862647B1 (fr) Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
EE200100431A (et) 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
EE04464B1 (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE200200095A (et) Sulfonüülkarboksamiidi derivaadid, nende kasutamine, ravim ja nende valmistamismeetod
HUP0301315A3 (en) Benzothiazole derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0402161A3 (en) Nicotin-or isonicotin benzothiazole derivatives, process for their preparation and pharmaceutical compositions containing them
IL165977A (en) Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
FR2816938B1 (fr) Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
FR2856685B1 (fr) Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
HUP0202071A3 (en) Mutilin derivatives, process for producing them and their use for producing pharmaceutical compositions having antibacterial effect
EE200200487A (et) Asetidiini derivaadid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EE04915B1 (et) Kinuklidiinderivaadid, nende valmistamismeetod, vahehendid, farmatseutiline kompositsioon ja nende kasutamine
EE05081B1 (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
EP1706412A4 (fr) Nouveaux derives de pyridine, leur procede de preparation et composition pharmaceutique en contenant
AU2002233463A1 (en) Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use
IL162765A (en) Diazabicycle derivatives, processes for their preparation, pharmaceutical compositions comprising them and their medical use
FR2840302B1 (fr) Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
EE200100422A (et) Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine
ATE323092T1 (de) Pyridopyrimidinon-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
PT1165081E (pt) Processo para a preparacao de preparacoes farmaceuticas cintendo tolperisona, para administracao oral
FR2883876B1 (fr) Derives d'indanyl-piperazines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
HUP0401522A2 (en) New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
FR2793794B1 (fr) Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
FR2842525B1 (fr) Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16